• Home
  • Agric
  • Sci & Tech
  • Health
  • Environment
  • Hausa News
  • More
    • Business/Banking & Finance
    • POLITICS
    • Entertainments & Sports
    • International
    • Investigation
    • Law & Human Rights
    • Africa
    • ACCOUNTABILITY/CORRUPTION
    • Hassan Gimba
    • Column
    • Prof. Jibrin Ibrahim
    • Prof. M.K. Othman
    • Defense/Security
    • Education
    • Energy/Electricity
    • Entertainment/Arts & Sports
    • Society and Lifestyle
    • Food & Agriculture
    • Health & Healthy Living
    • International News
    • Interviews
    • Investigation/Fact-Check
    • LAW & HUMAN RIGHTS
    • Oil & Gas/Mineral Resources
    • PRESS FREEDOM/JOURNALISM/PR
    • General News
    • Presidency
  • About Us
    • Contact Us
    • Board Of Advisory
    • Privacy Policy
    • Ethics Policy
    • Teamwork And Collaboration Policy
    • Fact-Checking Policy
    • Advertising
  • Media OutReach Newswire
    • Wire News
  • The Stories
Facebook Twitter Instagram
Trending
  • Smallholders unable to afford essential farm inputs, expert says
  • Farmers say high costs drive up catfish prices
  • NEWSAN calls for urgent repairs to sewage systems
  • Rising feed costs push farmers out of business
  • Naira slips to ₦1,379.99/$ as interbank FX turnover tops $500m
  • FAAC shares ₦2.44trn October revenue as statutory, VAT receipts decline
  • State trains veterinarians to expand rural services
  • UniCal Alumni turn to agribusiness to tackle graduate unemployment
Facebook Twitter Instagram YouTube
AsheNewsAsheNews
  • Home
  • Agric

    Smallholders unable to afford essential farm inputs, expert says

    November 19, 2026

    Farmers say high costs drive up catfish prices

    November 19, 2026

    Rising feed costs push farmers out of business

    November 19, 2026

    State trains veterinarians to expand rural services

    November 19, 2026

    UniCal Alumni turn to agribusiness to tackle graduate unemployment

    November 19, 2026
  • Sci & Tech

    Sultan inaugurates 500-seat ICT centre at Saki nursing college, backs health technology expansion

    November 19, 2026

    Linking payment systems key to Africa’s trade integration, officials say

    November 19, 2026

    CJID announces 2026 media, development conference

    November 18, 2026

    GOVMAIL adoption grows across Nigeria’s public sector

    November 17, 2026

    CADEF: Low public trust threatens Nigeria’s energy transition

    November 14, 2026
  • Health

    Foundation, ACF urge investment in boys’ development

    November 19, 2026

    Nigeria’s home care framework launched to support vulnerable people

    November 19, 2026

    WHO calls for coordinated action to curb antimicrobial resistance

    November 19, 2026

    Men should seek early medical care, NMA chief says

    November 19, 2026

    First lady calls for UN recognition of men’s day

    November 19, 2026
  • Environment

    NEWSAN calls for urgent repairs to sewage systems

    November 19, 2026

    Nigeria targets open defecation free status by 2030

    November 19, 2026

    Erosion puts Cross River transmission line at risk

    November 19, 2026

    Partnership targets open defecation in 8 states

    November 18, 2026

    Air Peace adds more daily flights between Lagos, Abuja

    November 18, 2026
  • Hausa News

    Foundation unveils public sector reform playbook

    November 12, 2026

    Tinubu asks Reps to approve N10.79tn external borrowing for 2026 budget

    November 11, 2026

    UNA signs MoU to launch air Bissau in Guinea-Bissau

    June 15, 2026

    Otti plans 250-room 5-star hotel in Umuahia

    April 11, 2026

    Anti-quackery task force seals 4 fake hospitals in Rivers

    August 29, 2025
  • More
    1. Business/Banking & Finance
    2. POLITICS
    3. Entertainments & Sports
    4. International
    5. Investigation
    6. Law & Human Rights
    7. Africa
    8. ACCOUNTABILITY/CORRUPTION
    9. Hassan Gimba
    10. Column
    11. Prof. Jibrin Ibrahim
    12. Prof. M.K. Othman
    13. Defense/Security
    14. Education
    15. Energy/Electricity
    16. Entertainment/Arts & Sports
    17. Society and Lifestyle
    18. Food & Agriculture
    19. Health & Healthy Living
    20. International News
    21. Interviews
    22. Investigation/Fact-Check
    23. LAW & HUMAN RIGHTS
    24. Oil & Gas/Mineral Resources
    25. PRESS FREEDOM/JOURNALISM/PR
    26. General News
    27. Presidency
    Featured
    Recent

    Smallholders unable to afford essential farm inputs, expert says

    November 19, 2026

    Farmers say high costs drive up catfish prices

    November 19, 2026

    NEWSAN calls for urgent repairs to sewage systems

    November 19, 2026
  • About Us
    1. Contact Us
    2. Board Of Advisory
    3. Privacy Policy
    4. Ethics Policy
    5. Teamwork And Collaboration Policy
    6. Fact-Checking Policy
    7. Advertising
    Featured
    Recent

    Smallholders unable to afford essential farm inputs, expert says

    November 19, 2026

    Farmers say high costs drive up catfish prices

    November 19, 2026

    NEWSAN calls for urgent repairs to sewage systems

    November 19, 2026
  • Media OutReach Newswire
    • Wire News
  • The Stories
AsheNewsAsheNews
Home»General News»COVID-19: AstraZeneca U.S. trial data confidence booster
General News

COVID-19: AstraZeneca U.S. trial data confidence booster

Abdallah el-KurebeBy Abdallah el-KurebeMarch 22, 2021No Comments5 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email

AstraZeneca’s COVID-19 vaccine performed better than expected in a major late-stage trial potentially paving the way for its emergency authorisation in the U.S. and bolstering confidence after numerous setbacks in Europe.

The drug maker said on Monday that trials in Chile, Peru and the U.S. found the vaccine, developed in conjunction with Oxford University, was 79 per cent effective in preventing symptomatic COVID-19 and crucially, posed no increased risk of blood clots.

It intends to request U.S. emergency authorisation in coming weeks.

More than a dozen European countries, including Germany and France, had halted use of the AstraZeneca vaccine earlier this month after some reports linked it to blood clots in a very small number of people.

They have since resumed inoculation after a regional regulator said it was safe but an opinion poll showed Europeans remained sceptical over its safety.

Hailed as a milestone in the fight against the COVID-19 pandemic when it first emerged as a vaccine contender last year, the AstraZeneca shot has since been dogged by confusion over its efficacy dosing regimen.

Its possible side-effects as well as supply setbacks in Europe, where the company has been at the centre of a growing conflict between Brussels and London over so-called ‘vaccine nationalism’.

The latest data should help address some of those concerns, analysts said.

Based on more than 32,000 people, the trial was larger and elderly volunteers featured more prominently than in previous trial results from the UK which had prompted some European countries to initially hold back using the AstraZeneca shot on older people.

“It is clear this vaccine has very good efficacy (remember that 60 per cent was, prior to any trials regarded as good target), and that this efficacy does not show a notable decline at older ages,” said Stephen Evans, Professor of Pharmacoepidemiology at the London School of Hygiene & Tropical Medicine.

AstraZeneca shares were up over one per cent in early London trading.

U.S. trials of rival vaccines from Pfizer and Moderna, which are already being deployed in the U.S., have showed efficacy rates of around 95 per cent.

But the AstraZeneca vaccine, which is already widely used outside the U.S., was seen as crucial to tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.

“I have just finished getting the (AstraZeneca) injection, there is no pain at the injection site, and there is no soreness of the body,” Taiwan Premier Su Tseng-chang told reporters as the island launched its inoculation campaign on Monday.

British Prime Minister Boris Johnson received his first dose of the AstraZeneca COVID-19 vaccine on Friday, saying he did not feel a thing.

And French President Emmanuel Macron said he would take the AstraZeneca vaccine if that’s what was offered after previously being quoted as saying the shot was “quasi-ineffective”.

AstraZeneca vaccine has already been granted a conditional marketing authorisation or emergency use in more than 50 countries, spanning four continents.

But it has yet to be approved in the U.S., where President Joe Biden is stepping up the federal response to the pandemic by expanding testing, ramping up vaccinations and boosting production.

University of Oxford professor Sarah Gilbert told BBC radio that work to prepare a submission for Emergency Use Authorisation in the U. S. will take a few weeks.

A company spokesman said the filing would likely be in the first half of April.

The American trial results have not yet been reviewed by independent researchers.

If the AstraZeneca vaccine gets U.S. approval, it will be the fourth after Pfizer, Moderna and Johnson & Johnson.

It uses a modified version of a chimpanzee common cold virus to teach the human body to make proteins from the novel Coronavirus to generate an immune response and prevent infection.

Scepticism over the shot started last year when the British drug maker and Oxford University published data with different efficacy readings due to a dosing measurement error.

Later analysis suggested the dosing interval rather than the amount of dose administers was responsible for the difference.

Many Asian countries heavily rely on the AstraZeneca vaccine to end the pandemic as the shot is being used in inoculation programmes in Australia, South Korea, the Philippines, Vietnam, Thailand and India.

Some states in India, which has the highest Coronavirus caseload after the U.S. and Brazil, are seeking to accelerate the vaccination drive as the country reported its most COVID-19 cases and deaths in months.

As vaccine demand raises at home, top producer the Serum Institute of India has delayed further shipments of the AstraZeneca shot to Brazil, Britain, Morocco and Saudi Arabia.

In Europe meanwhile, the EU has threatened to block exports of COVID-19 vaccines to Britain to safeguard scarce doses for its own citizens, with Commission President Ursula Von der Leyen, saying the epidemiological situation was worsening.

Reuters

AstraZeneca COVID-19 U.S. vaccine trial
Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Abdallah el-Kurebe
  • Website
  • Facebook
  • Twitter
  • LinkedIn

Related Posts

Naira slips to ₦1,379.99/$ as interbank FX turnover tops $500m

November 19, 2026

FAAC shares ₦2.44trn October revenue as statutory, VAT receipts decline

November 19, 2026

Foundation, ACF urge investment in boys’ development

November 19, 2026

Leave A Reply Cancel Reply

Smallholders unable to afford essential farm inputs, expert says

November 19, 2026

Farmers say high costs drive up catfish prices

November 19, 2026

NEWSAN calls for urgent repairs to sewage systems

November 19, 2026

Rising feed costs push farmers out of business

November 19, 2026
About Us
About Us

ASHENEWS (AsheNewsDaily.com), published by PenPlus Online Media Publishers, is an independent online newspaper. We report development news, especially on Agriculture, Science, Health and Environment as they affect the under-reported rural and urban poor.

We also conduct investigations, especially in the areas of ASHE, as well as other general interests, including corruption, human rights, illicit financial flows, and politics.

Contact Info:
  • 1st floor, Dogon Daji House, No. 5, Maiduguri Road, Sokoto
  • +234(0)7031140009
  • ashenewsdaily@gmail.com
Facebook Twitter Instagram Pinterest
© 2026 All Rights Reserved. ASHENEWS Daily Designed & Managed By DeedsTech

Type above and press Enter to search. Press Esc to cancel.